Completed PHASE2 INTERVENTIONAL 1-arm NCT00105950

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Breast

Interventions lapatinib

Updated 7 times since 2017 Last updated: Sep 24, 2015 Started: Mar 31, 2005 Primary completion: Sep 30, 2007 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00105950, this PHASE2 trial focuses on Neoplasms, Breast and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bayonne, France , Bethesda, United States , Brussels, Belgium , Chicago, United States , Detroit, United States , Durham, United States , Girona, Spain , London, United Kingdom , Lyon, France and 13 more locations